Galapagos 1Q25 update selects MCL as lead CAR-T indication, more data in 2025
Galapagos reported 1Q25 results with € 3.3b in cash and reiterated its cash burn guidance of € 175-225m (excl. restructuring costs). In the pipeline, the company provided more clarity on the path to market and selected MCL as lead indication, for which pivotal development is planned to begin in 2026. While Tecartus is already approved in that setting, it comes with burdensome toxicity and sales have plateaued. As such, we think GLPG5101's low rates of grade =3 CRS/ICANS could be a differentiator, and look forward to additional data by YE25. We reiterate our € 37 TP and Buy rating.Galapagos is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, addressing disease areas of high unmet medical need. Execution on its proprietary drug target discovery platform has delivered a pipeline that consists of three Phase 2, three Phase 1, five pre-clinical, and 20 discovery programs in inflammation, cystic fibrosis, or CF, osteoarthritis, and other indications. Co.'s highly flexible platform offers applicability across a broad set of therapeutic areas. Co.'s programs include filgotinib, GLPG1837, GLPG1690, GLPG2222, GLPG1972.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.